Actualités sur Krankheit
- plus
ZOE Study Reveals Eating a Plant Rich Diet Reduces Risk of Developing COVID-19 and Going to the Hospital
plusSchweizerischer Nationalfonds / Fonds national suisse
Clinical research: patients and the public have their say
Bern (ots) - The Swiss National Science Foundation has been funding clinical studies on under-researched topics in medicine since 2016. In a first, it successfully involved representatives of patients and the public in evaluating applications. The aim of the SNSF's Investigator Initiated Clinical Trials (IICT) programme is to answer medical questions that are important to society but not a priority for industry. This ...
plusServier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics
Paris (ots/PRNewswire) - Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological diseases. Under the collaboration ...
plusAlmirall and MC2 Therapeutics announce completion of decentralized procedure in Europe for the topical treatment of mild to moderate psoriasis vulgaris in adults
Barcelona, Spain and Copenhagen, Denmark (ots/PRNewswire) - - The successful completion of a decentralized procedure is the final step before national marketing authorizations can be granted by the European countries - MC2 Therapeutics has granted Almirall exclusive European rights to commercialize this topical ...
plusTianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
Wuhan (ots) - In September, 2020, Zhang Boli was awarded with the national honorary title, "the People's Hero," for his outstanding contribution to the country's fight against the COVID-19 pandemic. The decision was made to commend people who have made outstanding contribution in the fight, and carry forward their dedication and other noble qualities. This short ...
plusTianjin Haihe Media Group presents the story of Zhang Boli in fighting COVID-19 with TCM
Tianjin, China (ots) - In September, 2020, Zhang Boli was awarded with the national honorary title, "the People's Hero," for his outstanding contribution to the country's fight against the COVID-19 pandemic. The decision was made to commend people who have made outstanding contribution in the fight, and carry forward their dedication and other noble qualities. This ...
plus- 3
Vascudyne Announces Successful First Human Use of TRUE Vascular Graft for Hemodialysis Access
plus European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients
Brussels and Castres, France (ots/PRNewswire) - Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre today announced a strategic partnership in support of patients ...
plusPionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients
South San Francisco, Calif. and Cambridge, England (ots/PRNewswire) - - The partnership will support the progression of PY314, the first of Pionyr's Myeloid Tuning(TM) antibodies to enter the clinic - Pionyr will use Abcam's EPR20243 clone to evaluate TREM2 levels in tissue samples for potential future development ...
plusEpredia And Aiforia Announce Partnership For Global Distribution Of AI-powered Pathology Software
Portsmouth, N.h. (ots/PRNewswire) - Epredia, a global leader in precision cancer diagnostics, and Aiforia, a medical software company providing Artificial Intelligence (AI) based solutions for image analysis in pathology, have announced today that they have entered into a commercial distribution agreement for ...
plusDEBIOPHARM’S CD37 ANTIBODY DRUG CONJUGATE SHOWS PROMISING PHASE II RESULTS FOR THE TREATMENT OF B-CELL MALIGNANCIES
Lausanne, Switzerland (ots) - - Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin’s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease1 - Naratuximab ...
plusTNO research shows effectiveness of corona cannon
Rijswijk, Netherlands (ots/PRNewswire) - Addition due to incomplete information in the press release as sent on 4 June 2021 Analyses carried out by TNO in a BSL-3 laboratory cabinet showed that the corona gun had achieved a 94.9% reduction in the Covid -19 virus after 15 minutes. In the laboratory set-up, the (live) virus was located on stainless steel plates at 85 cm from the device. Earlier, the Dutch scientific ...
plusBiobeat Launches Wearable Continuous Ambulatory Blood Pressure Monitoring (ABPM) Device
Petah Tikva, Israel (ots/PRNewswire) - New Clinical Data Supports Use of Biobeat ABPM Cuffless-Monitor as Reliable and Accurate Solution for Out-of-Clinic Blood Pressure Monitoring Biobeat, a global leader in wearable remote patient monitoring solutions for the healthcare continuum, announced today the launch of its new wearable and continuous ambulatory blood pressure ...
plusEANS-News: Covid-19 Crisis Continues to Massively Burden the Aviation Sector: Flughafen Wien Group Handles 88.7% Fewer Passengers, Revenue Decline of 64.4%
issuer: Flughafen Wien AG Postfach 1 A-1300 Wien-Flughafen phone: +43 1 7007 - 23126 FAX: +43 1 7007 - 23806 mail: investor-relations@viennaairport.com WWW: http://viennaairport.com/unternehmen/investor_relations ISIN: AT00000VIE62 indexes: stockmarkets: Wien language: ...
plusCombined Apollon and Aion Formulations Kill Breast Cancer Cells Through Multiple Pathways
London and Toronto (ots/PRNewswire) - Apollon Formularies plc (AQSE: APOL) ("Apollon" or the "Company"), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ("Aion"), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint ...
plusMerck and BioMed X Institute Extend Collaboration to Continue Novel Research in Oncology and Autoimmunity
Darmstadt, Germany (ots/PRNewswire) - - Merck to support up to six additional research projects at the BioMed X Institute in Heidelberg within the next six years - Call for application for a global crowdsourcing project, 'Regulatory T Cell Dysfunction in Autoimmunity and Inflammaging' Merck, a leading science and ...
plusSemaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities
Bagsværd, Denmark (ots/PRNewswire) - Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to ...
plusswissstaffing - Verband der Personaldienstleister der Schweiz
Swiss Staffingindex - Second lockdown causes strain, but optimism for the summer
Un documentplusInvitation to Cosmo's GI Genius(TM) Q&A session for investors, analysts and journalist
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals N.V. (SIX: COPN) ( XETRA: C43) invites investors, financial analysts as well as business and trade media to a conference call Q&A session on the 4th of May 2021 to discuss GI Genius(TM), the first device approved by the US Food and Drug Administration[1] (FDA) that uses artificial intelligence to help detect potential ...
plusSchweizerischer Nationalfonds / Fonds national suisse
937 million Swiss francs for 3300 new research projects
Bern (ots) - In 2020, researchers submitted 8200 grant applications to the SNSF. 3300 of them were selected for funding in a competitive process. At short notice, the SNSF funded 73 projects on COVID-19. Thousands of SNSF-funded teams explore nature, technology and society. This generates knowledge that is a key driver of progress. In 2020, the SNSF invested 937 million francs in 3300 new projects, selected from 8200 ...
plusGalderma launches new Multichannel Medical Education platform: Inaugural webinar series on the impact of mask wearing on skin diseases
Lausanne, Switzerland (ots/PRNewswire) - - Launching in May, an inaugural four-part webinar series Unmasking Facial Skin & Dermatoses will feature expert presentations from world-renowned dermatologists - The program launches the Galderma Excellence in Multichannel Medical Education (GEMME) platform, demonstrating ...
plusAion Therapeutic's Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer Cells
Toronto (ots/PRNewswire) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or "Preparations") showed high efficacy in killing HER2+ breast ...
plus#RosaceaUnmasked by Galderma unites the rosacea community to shine light on the impact of essential COVID-19 mask-wearing this Rosacea Awareness Month
Lausanne, Switzerland (ots/PRNewswire) - - Rosacea sufferers join forces this Rosacea Awareness Month to bravely share the personal impact essential COVID-19 mask-wearing has on their skin condition - #RosaceaUnmasked encourages rosacea sufferers to speak with a doctor or dermatologist about the burden of regular ...
plusPrecision NanoSystems Announces New Cell Therapy Reagent for Lipid Nanoparticle -based mRNA Delivery to T Cells
Vancouver, Bc (ots/PRNewswire) - Precision NanoSystems (PNI), a global leader in innovative solutions for genetic medicine development, today launched the GenVoy-ILM(TM) T Cell Kit for mRNA to enable lipid nanoparticle (LNP)-based ex vivo gene transfer. Scientists can now use mRNA-LNP to efficiently and reproducibly ...
plusDEBIOPHARM COLLABORATES WITH INNOCENTIVE FOR THE LAUNCH OF A GLOBAL CHALLENGE TO DEVELOP A SINGLE-DOSE mRNA COVID-19 VACCINE
Lausanne, Switzerland (ots) - - Currently approved COVID-19 vaccines based on messenger RNA (mRNA) technology require two injections, given several weeks apart, for optimal protection against the virus - Debiopharm has launched a vaccine innovation challenge to a pool of international “problem Solvers” within ...
plusVidac Pharma Secures EUR 20m Capital Commitment From GEM
Ness-Ziona, Israel (ots/PRNewswire) - Vidac Pharma LTD (Vidac) a clinical-stage Israel biopharmaceutical company, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment. Under the agreement, GEM commits to provide Vidac with a share subscription facility of up to EUR 20 million for a 36-month term ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Novel antibiotic deceives bacteria through mimicry
Bern (ots) - Most antibiotics need to penetrate their target bacteria. But Darobactin, a newly discovered compound, is much too large to do so. Nonetheless, it kills many antibiotic-resistant pathogens - by exploiting a tiny weak spot on their surface. Basel researchers have now revealed the amazing mechanism at play and thereby opened the door to developing completely new medicines. An increasing number of bacterial ...
plusCosmo announces FDA approval of GI Genius(TM) intelligent endoscopy module, its revolutionary Artificial Intelligence device for lesion detection during colonoscopy
Dublin (ots/PRNewswire) - Cosmo Pharmaceuticals NV (SIX: COPN) today announced the FDA approval of GI Genius(TM) intelligent endoscopy system, its revolutionary device for lesion detection during colonoscopy. The GI Genius module FDA approval marks a pivotal milestone for Cosmo after more than 10 years of research ...
plusBionical Emas launches Managed Access Program for JZP 458 - a recombinant Crisantaspase produced in Pseudomonas fluorescens
Willington, England (ots/PRNewswire) - Bionical Emas, a global specialist Clinical Research Organization (CRO) has today announced the launch of a Managed Access Program for Jazz Pharmaceuticals' medicinal product JZP-458 for the treatment of patients with Acute Lymphoblastic Leukaemia (ALL) and Lymphoblastic ...
plus